AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05442476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
Study NCT05442476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle Energy Technique
Description: The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
Study NCT05442476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional physiotherapy
Description: conventional physiotherapy
Study NCT05442476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: conventional physiotherapy
Study NCT06107881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Evaluation and training with magnification or visual assistive devices for visually-impaired adults
Study NCT06107881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Vision Rehabilitation
Description: Evaluation and training with magnification or visual assistive devices for visually-impaired adults
Study NCT05796375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
Study NCT05796375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
Study NCT05796375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck urine test
Description: The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
Study NCT05796375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert Bladder Cancer Monitor urine test
Description: A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
Study NCT05185713 — intervention group
Intervention type: OTHER
Intervention: This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
Description: This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
Study NCT04561765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCanCope
Description: The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
Study NCT04561765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCanCope+Contingency Management
Description: In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
Study NCT05270252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning and Care
Description: The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright \& Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care.
Study NCT06414993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for Emerging Adults (CM-EA)
Description: After CM-EA is introduced, a contingency contract is developed between a parent and emerging adult (EA) that provides EAs with rewards for negative drug screens and completion of developmentally appropriate goals to build recovery capital, along with disincentives for positive screens or engaging in inappropriate behaviors. Concurrently, parents are taught to conduct random urine drug screens. Additionally, parents are trained to complete functional analyses in collaboration with their EA to identify the EA's triggers for poly-substance use and negative behaviors. Individualized triggers are targeted via self-management planning and drug refusal skills training. At the end of CM-EA, plans are made with the family for sustaining abstinence and improvements in other behaviors.
Study NCT06414993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services
Description: Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation, employment). After needs are identified, a peer worker addresses needs through informational resources and community referrals and engages clients in positive recreational activities offering advice, hope and empowerment to encourage steps toward a reduction in substance use and eventual abstinence. When desired, peer workers also link clients to a broader recovery peer community. In addition, the peer worker will dedicate time to increasing recovery capital via improving skills related to V/E advancement using a workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health Providers, for which peer workers will be trained.
Study NCT04433988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg SR tablet
Study NCT04433988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT05765578 — intervention group
Intervention type: BIOLOGICAL
Intervention: Moderna COVID-19 Vaccine
Description: Sterile liquid for injection. Intervention not administered through this study.
Study NCT05765578 — intervention group
Intervention type: BIOLOGICAL
Intervention: Moderna mRNA1273.222 Booster
Description: Sterile liquid for injection. Intervention not administered through this study.
Study NCT05765578 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pfizer COVID-19 Vaccine
Description: Sterile liquid for injection. Intervention not administered through this study.
Study NCT05765578 — intervention group
Intervention type: BIOLOGICAL
Intervention: Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)
Description: Sterile liquid for injection. Intervention not administered through this study.
Study NCT05765578 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)
Description: Sterile liquid for injection. Intervention not administered through this study.
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: Alectinib 600 mg/BID
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Brigatinib
Description: 180 mg/daily
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Lorlatinib 100 mg
Description: 100 mg/daily
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Osimertinib
Description: 80 mg/daily
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Sotorasib
Description: 960 mg/daily
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Dabrafenib
Description: 150 mg/BID
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Trametinib
Description: 2 mg/daily
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Selpercatinib
Description: 160 mg/BID
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Description: 200 mg intravenous every 21 days
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Cemiplimab
Description: 350 mg intravenous every 21 days
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: 240 mg intravenous every 14 days
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: AUC4/AU5 intravenous every 21 days
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Description: 500 mg/mq intravenous every 21 days
Study NCT06532149 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: 175 mg/mq intravenous every 21 days
Study NCT06413082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torasemide
Description: The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
Study NCT06413082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
Study NCT04995224 — intervention group
Intervention type: OTHER
Intervention: Assessment of Psychophysiological factors
Description: Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Study NCT04995224 — intervention group
Intervention type: BIOLOGICAL
Intervention: Assessment of Biological factors
Description: Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
Study NCT04995224 — intervention group
Intervention type: GENETIC
Intervention: Assessment of Genetics
Description: Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Study NCT04995224 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment of Quality of Life
Description: Investigating QOL by questionnaires.
Study NCT04995224 — intervention group
Intervention type: BIOLOGICAL
Intervention: Assessment of Biological factors
Description: Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
Study NCT05107726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE Group
Description: This group will practice time-restricted eating
Study NCT06230211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
Study NCT06230211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Voice
Description: Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
Study NCT06071689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: screw retained prosthesis
Description: all-on-4 screw-retained prosthesis.
Study NCT05688475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Specified dose on specified days
Study NCT05688475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT04558840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macromastia
Description: Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
Study NCT06005207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone vaginal sustained-release gel
Description: 90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
Study NCT03995953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)
Description: The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for family members to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
Study NCT03995953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated wellness care (IWC) clinics
Description: IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
Study NCT04845503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Radiotherapy
Description: Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
Study NCT05366738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via tablet
Study NCT05366738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via sprinkle pellets
Study NCT05039892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D185
Description: All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
Study NCT05259280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellinks
Description: Digital health and virtual care program for COPD management.
Study NCT06101589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.
Description: 5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
Study NCT06101589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil in 1 ml ethyl oleate with no vitamin D3 content
Study NCT05243511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital ACT
Description: Participants in this arm receive Digital ACT as well as standard of care.
Study NCT05243511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Symptom Tracker
Description: Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
Study NCT05461534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness yoga
Description: Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
Study NCT04875143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus aurantium L.
Description: In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
Study NCT04875143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Citrus aurantium L.
Description: In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
Study NCT04969302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured
Study NCT05097963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound Shear Wave Elastography
Description: Software to determine stiffness of liver for evaluating liver fibrosis.
Study NCT05341141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen glove and sock
Description: Preparation of frozen glove and sock: 4℃ for 3 hours.
Study NCT05341141 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ddEC-ddT
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
Study NCT05341141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddEC-ddT
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
Study NCT04962308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Inactivated Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
Study NCT04962308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The SARS-CoV-2 Inactivated Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
Study NCT06212336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Interventional Medicinal Product (IMP)
Study NCT06212336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Interventional Medicinal Product (IMP)
Study NCT06212336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Control arm
Study NCT06212336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Interventional Medicinal Product (IMP)
Study NCT05756959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM
Description: PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
Study NCT05756959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral defocus spectacles
Description: plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
Study NCT05756959 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single vision spectacles
Description: Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
Study NCT05756959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacles
Description: Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
Study NCT05666167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Telehealth Exercise Sessions with text messaging plus booster sessions
Description: Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.